UK Puberty Blocker Trial Paused After MHRA Raises New Safety Concerns
A significant clinical trial examining the use of puberty blockers for children and young people experiencing gender dysphoria has been temporarily suspended. This decision follows the Medicines and Healthcare products Regulatory Agency (MHRA) expressing fresh concerns about the wellbeing of participants, specifically highlighting the "unquantified risk" of potential long-term biological harms.
Regulator Demands Higher Age Limit
The MHRA has formally requested that the trial's minimum age limit be raised from 10 to 14 years old. In a detailed letter, the regulator stated that due to the significant and as yet unquantified risks, a "graded or stepwise approach" should be adopted, beginning with older adolescents. The agency emphasized that biological safety has not been definitively demonstrated for the proposed younger cohort.
The trial, known as the Pathways study and sponsored by King's College London, was designed to recruit approximately 226 young people aged between 10 and nearly 16. Recruitment has now been halted and will not commence until these critical safety issues are thoroughly addressed. The MHRA is scheduled to meet with representatives from King's College London next week to discuss the concerns in detail.
Political and Public Scrutiny Intensifies
The pause occurs amidst considerable political and public debate. The trial was originally recommended by the landmark Cass Review into children's gender services. Baroness Hilary Cass, who led that review, has previously stated her report "uncovered a very weak evidence base" for the benefits of puberty blockers but concluded that a supervised trial was the only way to establish clearer evidence.
However, the trial has faced opposition from various quarters. Legal action has been initiated against the government, and public figures, including author JK Rowling, have voiced strong criticism. Rowling described the research as "an unethical experiment on children who can't give meaningful consent."
Government and Institutional Responses
A spokesperson for the Department of Health and Social Care reiterated that the safety and wellbeing of children involved are paramount. They confirmed that preparations for the trial have been paused while the MHRA and clinical leaders work through the new concerns. The trial will only proceed if expert scientific and clinical evidence concludes it is both safe and necessary.
Health Secretary Wes Streeting has acknowledged feeling "uncomfortable" with the use of puberty-suppressing hormones on young people but stated it is his responsibility to follow expert advice, maintaining that proceeding with a trial is the "right thing to do."
In contrast, Conservative figures have been critical. Leader Kemi Badenoch previously urged the health secretary to stop the trial "before more damage is done to children." Shadow equalities minister Claire Coutinho called the pause a "huge win," accusing the government of having "ignored warnings."
Academic Perspective and Future Steps
A spokesperson for King's College London affirmed that the wellbeing of young people and their families remains the top priority. They stated the institution will continue to collaborate with the MHRA to support its further review of the trial, which was designed with "scientific rigour at its core." They emphasized the importance of such rigour for building a reliable evidence base to aid future clinical decisions.
Baroness Cass has argued that a supervised clinical trial is "better" than the alternative of young people potentially sourcing unregulated drugs through other channels. The future of the trial now hinges on the outcome of the forthcoming discussions between the regulator and the research sponsors, with the raised age limit being a central point of negotiation.
